MEDIAN Technologies concludes a new collaboration agreement with the world’s largest CRO
- This new agreement is concluded for a term of three years; it follows the collaboration agreement concluded on February 16th, 2012
- This new agreement includes modification of the CRO consideration clauses regarding businesses contracted by MEDIAN Technologies
MEDIAN Technologies (ALMDT.PA), a leading medical imaging solutions and service provider for image interpretation and management in oncology, today announces the signature of a new collaboration agreement with the world’s largest CRO (Contract Research Organization) for a term of three years. This new agreement, signed on May 3rd, 2016, follows the previous agreement concluded on February 16th, 2012.
The renewal of this collaboration agreement includes a modification of the CRO consideration regarding businesses contracted by MEDIAN Technologies, which is more adapted to the context and defined after a collaboration which has started more than four years ago.
It is recalled that, on February 16th, 2012, MEDIAN Technologies concluded and announced through two press releases the signature of a collaboration agreement with the world’s largest biopharmaceutical development services provider (CRO – Contract Research Organization) as its partner. This previous agreement allowed the partner, in case of exercise of its shares warrants, which were solely exercisable through set-off of its receivables held against the Company, to hold up to 15% of the share capital of MEDIAN Technologies. The parties concluded an agreement on May 3rd, 2016 to cancel this scheme: the parties have decided to cancel all the shares warrants held by the partner since none of them has been exercised.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”